Luas Diagnostics of Guildford, Surrey, today announced the launch of a test to determine immunity to Covid-19 post infection or vaccination.
The product, which is manufactured by Chembio Diagnostics Systems of New York, uses a fingerstick of blood for the detection, differentiation and quantification of IgM and IgG receptor binding domain antibodies to SARS-CoV-2. The results are read and stored in a portable reader which provides semi-quantitative results in either laboratory or remote settings. The total time to result is 15 minutes and the antibody response is represented numerically.
William James, Professor of Virology at the Sir William Dunn School of Pathology at the University of Oxford stated:
“Antibodies in the blood, induced either by SARS-CoV-2 infection or, even more importantly, by vaccination, are critical in protecting people from future infection and severe Covid19 disease. It is clear that the higher the concentration of specific, anti-SARS-CoV-2 antibody in the blood, the higher the level of protection. We now know that immunization with the approved vaccines generates high levels of antibody that provide good levels of protection against infection. This is why we recommend everyone who can, should get vaccinated at the earliest opportunity, and why it is so important to make vaccines available across the world.
“The availability of a simple and rapid blood test that can quantify antibody levels is therefore an important factor in monitoring the likely level of immune protection in both convalescent individuals and vaccinees and could be useful in decisions on whether and when to give booster jabs. Being able to distinguish the IgM from the IgG class of antibody response will also provide potentially useful information about the stage of a person’s immune response, and its likely persistence over time”
Brendan Farrell, CEO of Luas Diagnostics, commented: “We are excited to form a partnership with Chembio to market their test to determine antibody response post infection or vaccination. A recent study has shown that 10-15% of people, particularly among the higher age group, may not produce antibodies even after the second dose of vaccine and thus may have limited protection against the virus.”